EGFR and non-small cell lung carcinoma: The cobas®EGFR Mutation v2 was the first to be approved using both tissue and plasma from patients with non-small cell lung cancer (NSCLC) that identifies 42 mutations in exons 18, 19, 20, and 21 of the epidermal growth factor receptor (EGFR) gene, including the T790M resistant mutation [27].